钠-葡萄糖协同转运蛋白2抑制剂与胰高血糖素样肽1受体激动剂对2型糖尿病退伍军人肾脏及临床结局的影响 - Suppr

Suppr

超能文献

Sodium-Glucose Cotransporter-2 Inhibitors versus Glucagon-Like Peptide 1 Receptor Agonists Effects on Kidney and Clinical Outcomes in Veterans with Type 2 Diabetes.

作者信息

Morello Candis M, Awdishu Linda, Lam Stepfanie, Heman Amy, Bounthavong Mark

机构信息

San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, La Jolla, California.

Veterans Affairs San Diego Healthcare System, San Diego, California.

出版信息

Kidney360. 2024 Nov 1;5(11):1633-1643. doi: 10.34067/KID.0000000597. Epub 2024 Oct 3.

DOI:10.34067/KID.0000000597

PMID:39361784

Abstract

摘要

相似文献

Sodium-Glucose Cotransporter-2 Inhibitors versus Glucagon-Like Peptide 1 Receptor Agonists Effects on Kidney and Clinical Outcomes in Veterans with Type 2 Diabetes.钠-葡萄糖协同转运蛋白2抑制剂与胰高血糖素样肽1受体激动剂对2型糖尿病退伍军人肾脏及临床结局的影响

Kidney360. 2024 Nov 1;5(11):1633-1643. doi: 10.34067/KID.0000000597. Epub 2024 Oct 3.

Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists and Sodium/Glucose Cotransporter 2 Inhibitors in Preventing Chronic Kidney Failure and Mortality in Patients With Type 2 Diabetes and CKD.胰高血糖素样肽-1受体激动剂与钠/葡萄糖协同转运蛋白2抑制剂在预防2型糖尿病合并慢性肾脏病患者慢性肾衰竭及死亡方面的比较疗效

Am J Kidney Dis. 2025 Apr 29. doi: 10.1053/j.ajkd.2025.03.016.

Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with kidney outcomes in patients with type 2 diabetes: A systematic review and network meta-analysis.钠-葡萄糖共转运蛋白 2 抑制剂、胰高血糖素样肽 1 激动剂和二肽基肽酶 4 抑制剂与 2 型糖尿病患者肾脏结局的关系：系统评价和网络荟萃分析。

PLoS One. 2022 Apr 14;17(4):e0267025. doi: 10.1371/journal.pone.0267025. eCollection 2022.

Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes.用于慢性肾病和糖尿病患者的胰高血糖素样肽1（GLP-1）受体激动剂。

Cochrane Database Syst Rev. 2025 Feb 18;2(2):CD015849. doi: 10.1002/14651858.CD015849.pub2.

Comparison of New-Onset Peripheral Artery Disease in Patients With Type 2 Diabetes Exposed to Sodium-Glucose Cotransporter-2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, or Glucagon-Like Peptide-1 Agonists: A Population-Based Cohort Study.2型糖尿病患者中使用钠-葡萄糖协同转运蛋白2抑制剂、二肽基肽酶4抑制剂或胰高血糖素样肽1激动剂后新发外周动脉疾病的比较：一项基于人群的队列研究。

J Am Heart Assoc. 2025 Jun 3;14(11):e034175. doi: 10.1161/JAHA.123.034175. Epub 2025 May 22.

Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.钠-葡萄糖共转运蛋白 2（SGLT-2）抑制剂和胰高血糖素样肽-1（GLP-1）受体激动剂治疗 2 型糖尿病：随机对照试验的系统评价和网络荟萃分析。

BMJ. 2021 Jan 13;372:m4573. doi: 10.1136/bmj.m4573.

Genetic variability in sodium-glucose cotransporter 2 and glucagon-like peptide 1 receptor effect on glycemic and pressure control in type 2 diabetes patients treated with SGLT2 inhibitors and GLP-1RA in the everyday clinical practice.在日常临床实践中，钠-葡萄糖协同转运蛋白2和胰高血糖素样肽1受体的基因变异性对接受钠-葡萄糖协同转运蛋白2抑制剂和胰高血糖素样肽1受体激动剂治疗的2型糖尿病患者血糖和血压控制的影响。

Front Endocrinol (Lausanne). 2025 Jul 7;16:1547920. doi: 10.3389/fendo.2025.1547920. eCollection 2025.

SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline.钠-葡萄糖协同转运蛋白 2 抑制剂或胰高血糖素样肽-1 受体激动剂治疗 2 型糖尿病成人患者：临床实践指南。

BMJ. 2021 May 11;373:n1091. doi: 10.1136/bmj.n1091.

Patient-important outcomes in type 2 diabetes: The paradigm of the sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists.2 型糖尿病的患者重要结局：钠-葡萄糖共转运蛋白 2 抑制剂和胰高血糖素样肽-1 受体激动剂的范例。

Diab Vasc Dis Res. 2024 Jul-Aug;21(4):14791641241269743. doi: 10.1177/14791641241269743.

Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas for Sight-Threatening Diabetic Retinopathy.胰高血糖素样肽-1 受体激动剂、钠-葡萄糖协同转运蛋白 2 抑制剂、二肽基肽酶-4 抑制剂和磺脲类药物治疗威胁视力的糖尿病视网膜病变的疗效比较。

Ophthalmol Retina. 2024 Oct;8(10):943-952. doi: 10.1016/j.oret.2024.05.003. Epub 2024 May 11.

引用本文的文献

Kidney Outcomes With Glucagon-Like Peptide-1 Receptor Agonists Versus Other Glucose-Lowering Agents in People With Type 2 Diabetes: A Systematic Review and Meta-Analysis of Real-World Data.2型糖尿病患者中胰高血糖素样肽-1受体激动剂与其他降糖药物的肾脏结局：真实世界数据的系统评价和荟萃分析

Diabetes Metab Res Rev. 2025 Jul;41(5):e70066. doi: 10.1002/dmrr.70066.

Training the Next Generation of Pharmacist Educators (NextGenRxEd): Outcomes from a Longitudinal 4-Year Teaching and Research Program.培养下一代药剂师教育工作者（NextGenRxEd）：一项为期四年的纵向教学与研究项目的成果

Pharmacy (Basel). 2025 Apr 22;13(3):58. doi: 10.3390/pharmacy13030058.

The use of SGLT2 inhibitors and GLP-1 receptor agonists in older patients: a debate on approaches in CKD and non-CKD populations.老年患者中钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂和胰高血糖素样肽-1（GLP-1）受体激动剂的应用：关于慢性肾脏病（CKD）和非CKD人群治疗方法的争论

Clin Kidney J. 2024 Dec 2;18(2):sfae380. doi: 10.1093/ckj/sfae380. eCollection 2025 Feb.

Correction: Sodium-Glucose Cotransporter-2 Inhibitors versus Glucagon-Like Peptide 1 Receptor Agonists Effects on Kidney and Clinical Outcomes in Veterans with Type 2 Diabetes.更正：钠-葡萄糖协同转运蛋白2抑制剂与胰高血糖素样肽1受体激动剂对2型糖尿病退伍军人肾脏及临床结局的影响

Kidney360. 2025 Jan 1;6(1):177. doi: 10.34067/KID.0000000667.

本文引用的文献

Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial.在 FLOW 试验中，有 2 型糖尿病和慢性肾病的参与者使用和不使用 SGLT2 抑制剂的司美格鲁肽的影响。

Nat Med. 2024 Oct;30(10):2849-2856. doi: 10.1038/s41591-024-03133-0. Epub 2024 Jun 24.

Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.司美格鲁肽对 2 型糖尿病患者慢性肾脏病的影响。

N Engl J Med. 2024 Jul 11;391(2):109-121. doi: 10.1056/NEJMoa2403347. Epub 2024 May 24.

KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.KDIGO 2024慢性肾脏病评估与管理临床实践指南

Kidney Int. 2024 Apr;105(4S):S117-S314. doi: 10.1016/j.kint.2023.10.018.

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.原发性肾脏疾病对恩格列净治疗慢性肾脏病患者疗效的影响：EMPA-KIDNEY 试验的二次分析。

Lancet Diabetes Endocrinol. 2024 Jan;12(1):51-60. doi: 10.1016/S2213-8587(23)00322-4. Epub 2023 Dec 4.

Long-Term, Real-World Kidney Outcomes with SGLT2i versus DPP4i in Type 2 Diabetes without Cardiovascular or Kidney Disease.在没有心血管或肾脏疾病的 2 型糖尿病患者中，SGLT2i 与 DPP4i 的长期真实世界肾脏结局。

Clin J Am Soc Nephrol. 2023 Sep 1;18(9):1153-1162. doi: 10.2215/CJN.0000000000000218. Epub 2023 Jun 29.

Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.药物治疗 2 型糖尿病的获益与危害：随机对照试验的系统评价和网络荟萃分析。

BMJ. 2023 Apr 6;381:e074068. doi: 10.1136/bmj-2022-074068.

Comparison of the Impact of SGLT2-Inhibitors and Exenatide on Body Fat Composition.钠-葡萄糖协同转运蛋白2抑制剂与艾塞那肽对身体脂肪成分影响的比较

J Coll Physicians Surg Pak. 2023 Mar;33(3):308-313. doi: 10.29271/jcpsp.2023.03.308.

Efficacy and safety of drugs for people with type 2 diabetes mellitus and chronic kidney disease on kidney and cardiovascular outcomes: A systematic review and network meta-analysis of randomized controlled trials.2型糖尿病合并慢性肾脏病患者使用药物对肾脏和心血管结局的疗效及安全性：一项随机对照试验的系统评价和网状荟萃分析

Diabetes Res Clin Pract. 2023 Apr;198:110592. doi: 10.1016/j.diabres.2023.110592. Epub 2023 Feb 25.

The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease.在伴有慢性肾脏疾病的 2 型糖尿病患者中，每周一次司美格鲁肽治疗的肾脏结局试验（FLOW）的原理、设计和基线数据。

Nephrol Dial Transplant. 2023 Aug 31;38(9):2041-2051. doi: 10.1093/ndt/gfad009.

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023.9. 血糖治疗的药物学方法：2023 年糖尿病的护理标准。

Diabetes Care. 2023 Jan 1;46(Suppl 1):S140-S157. doi: 10.2337/dc23-S009.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验